Bafiertam (Monomethyl Fumarate) Patent Expiration, LOE Window & CMS Spending

Bafiertam (Monomethyl Fumarate) by Banner Life Sciences: FDA Orange Book LOE 2035-02-27, 0 AB generics, $11.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBanner Life Sciences
FDA Application & PathwayN210296 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-02-27
Orange Book Patents (*PED Extensions)21 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.5M
2024 Medicare Part D Spend$8.2M
2024 Medicaid Spend$3.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel